NEW YORK (GenomeWeb News) – Privately-held US Genomics has raised $1 million through a sale of equity and debt securities to company executives and directors, and may raise up to $1 million more, according to a filing with the US Securities and Exchange Commission.
The Woburn, Mass.-based firm offers tools used in the extraction of high-grade DNA, tagging, microfluidics, and genomic mapping, for a range of purposes such as diagnostics, biosecurity, and food and drug monitoring.
In 2008, the firm reeled in a $4.5 million investment from Becton Dickinson as part of a collaborative agreement to develop molecular diagnostic technologies for human pathogens.
The company was not immediately available for comment to discuss its plans for the investment.